Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy
University of Pittsburgh Medical Center · Cedars-Sinai Medical Center · +8 more institutions
Abstract
Fabry disease (alpha-galactosidase A deficiency) is an X-linked recessive lysosomal storage disorder. Although the disease presents in childhood and culminates in cardiac, cerebrovascular, and end-stage renal disease, diagnosis is often delayed or missed. This paper reviews the key signs and symptoms of Fabry disease and provides expert recommendations for diagnosis, follow-up, medical management, and the use of enzyme replacement therapy. Recommendations are based on reviews of the literature on Fabry disease, results of recent clinical trials, and expertise of the authors, all of whom have extensive clinical experience with Fabry disease and lysosomal storage disorders and represent subspecialties involved…
Citation impact
- FWCI
- 19.62
- Percentile
- 100%
- References
- 59
Authors
9- RJRobert J. DesnickCorresponding
University of Pittsburgh Medical Center, Cedars-Sinai Medical Center, Hôpital Européen, National Institutes of Health, Hôpital Européen Georges-Pompidou, Cincinnati Children's Hospital Medical Center, Icahn School of Medicine at Mount Sinai, University of Minnesota System, National Institute of Neurological Disorders and Stroke, University of California, San Francisco
- RBRoscoe Brady
Hôpital Européen Georges-Pompidou, Cedars-Sinai Medical Center
- JBJohn Barranger
Cedars-Sinai Medical Center, Hôpital Européen Georges-Pompidou
- AJAllan J. Collins
Hôpital Européen Georges-Pompidou, Cedars-Sinai Medical Center
- DPDominique P. Germain
Hôpital Européen Georges-Pompidou, Cedars-Sinai Medical Center
Topics & keywords
- Medicine
- Enzyme replacement therapy
- Fabry disease
- Disease
- Intensive care medicine
- Disease management
- Pediatrics
- Pathology
- Good health and well-being